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Abstract Factor XIII (FXIII) is necessary for cross
linking of fibrin strands and generation of stable fibrin clot.
FXIII Val34Leu is a common genetic single nucleotide
polymorphism that has been associated with accelerated
fibrin stabilization and reduced rate of fibrinolysis. The
contribution of Val34Leu to long term risk of recurrent
myocardial infarction (MI) in patients with coronary
stenting has not been conclusively established. The
objective of the study was to examine the effects of
Val34Leu on fibrin generation, platelet aggregation, and
long term clinical outcomes in patients with coronary
artery disease treated with dual antiplatelet therapy.
Patients with angiographically documented coronary artery
disease who were treated with aspirin and clopidogrel were
enrolled (n = 211). Light transmittance aggregometry and
plasma fibrin clot formation using thrombelastography
(TEG) were determined. Genotyping of Val34Leu was
performed using Taqman assay. Clinical events during
follow up were recorded. Homozygous carriers of 34Leu
variant had significantly shorter fibrin clot formation time
as compared to wild type individuals (TEG K: 1.27 ± 0.3
vs. 1.68 ± 1.1 min, p = 0.011). The Val34Leu variant was
associated with gene dose dependent increased risk of MI
(log rank, p = 0.002) or occurrence of composite of MI
and CV death (log rank, p = 0.005) with highest event
rates observed in homozygous carriers of 34Leu. In sum-
mary, FXIII Val34Leu polymorphism was associated with
increased rate of fibrin stabilization in homozygous carriers
of the variant and may increase risk of recurrent MI and
death in patients with angiographically established coro-
nary artery disease treated with dual antiplatelet therapy.
Keywords Acute myocardial infarction  Genetic
polymorphism  Coagulation  Platelet function tests 
Thrombelastography
Introduction
Despite advances in medical therapy, recurrent myocardial
infarction (MI) remains a significant contributor to long
term morbidity and mortality in patients with coronary
artery disease. In patients treated with clopidogrel after
coronary stenting, high residual platelet reactivity induced
by adenosine diphosphate (ADP) has been associated with
increased risk of stent thrombosis and recurrent MI [1–3].
During acute coronary syndromes (ACS), activation of
coagulation and thrombin generation is a central step pre-
ceding coronary thrombosis and treatment with heparin or
low molecular weight heparin is standard of care in the
initial in-hospital management of ACS [4]. Risk associated
with continued prothrombotic changes related to vascular
inflammation may be an important mediator of long term
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recurrent risk of ischemic events in patients with coronary
stenting [5–10]. While large scale efforts have been
directed at identifying genetic variants causally linked to
the development of coronary artery disease, fewer efforts
have been directed specifically at identifying single
nucleotide polymorphisms (SNPs) associated with recur-
rent ischemic risk in patients with established coronary
artery disease [11].
Coagulation factor XIII (FXIII) plays an important role
in the final stages of the coagulation cascade and the reg-
ulation of fibrinolysis, and it is essential in the formation of
stable and fibrinolysis resistant fibrin clot [12]. FXIII is a
glycoprotein tetramer (A2B2) consisting of two catalytic A
subunits encoded by the F13A1 gene mapping to 6p25.3–
p24.3, and two carrier/inhibitory B subunits encoded by the
F13B gene mapping to 1q31–q32.1. When activated, FXIII
covalently cross-links fibrin forming a stiff fibrin network.
The F13A1 gene is characterized by significant allelic
heterogeneity, and several polymorphisms have been
identified with varied functional importance [12]. The
F13A1 c.103G[T (p.Val35Leu) rs5985 SNP, hereinafter
referred to as its legacy name of Val34Leu, is critically
located near the thrombin activation site (R37-G38) of
FXIII-A and has been demonstrated to affect the rate of
FXIII activation peptide cleavage by thrombin, resulting in
faster FXIII activation and more rapid fibrin clot formation.
This variant is present in approximately 40 % of white
subjects [13–15]. A large proportion of circulating FXIII-A
is stored in platelets and released upon platelet activation.
The activated FXIII (FXIIIa) has been shown to support
platelet activation and enhance thrombus formation by
matrix proteins through interactions with the platelet gly-
coprotein aIIbb3 receptor and integrin aVb3 [16]. However,
the effect of Val34Leu polymorphism on clopidogrel
platelet inhibition in subjects with coronary artery disease
has not been examined [12].
We hypothesized that the Val34Leu polymorphism is a
associated with faster fibrin stabilization and increased risk
of recurrent MI during follow up in patients with established
coronary artery disease treated with dual antiplatelet therapy.
Materials and methods
Patients
The study protocols were approved by Indiana University
School of Medicine’s Institutional Review Board for
Research. Informed consent was obtained from all subjects.
Subjects with established angiographic diagnosis of coro-
nary artery disease who were treated with dual antiplatelet
therapy after coronary stenting or ACS with clopidogrel
and aspirin 81–325 mg daily were enrolled. To be included
in this study, subjects either had to have been taking
clopidogrel 75 mg daily for at least 5 days prior to
enrollment or had received a clopidogrel 600 mg loading
dose at least 6 h prior to blood draws. Exclusion criteria
included a history of drug or alcohol abuse, bleeding dis-
order, myelodysplastic or myeloproliferative disorders,
chronic liver disease, current warfarin use, pregnancy,
thrombocytopenia (platelet count less than 100,000/mm3),
and glycoprotein IIb/IIIa antagonist use.
Blood samples
Peripheral venous blood samples were drawn at least 6 h
after administration of a clopidogrel loading dose or prior to
the next clopidogrel dose in patients on clopidogrel main-
tenance dosing for platelet assays. All blood samples were
directly transferred into vacutainer tubes containing 3.2 %
Na-citrate. Citrate plasma was obtained from blood samples
obtained prior to percutaneous coronary interventions and
prior to administration of anticoagulants by centrifugation at
2,0009g for 15 min and was stored at -80 C until analysis.
Platelet aggregation studies
Ex vivo platelet function was assessed by light transmit-
tance aggregometry (LTA) at 37 C with an Optical Lumi-
Aggregometer (Model 700 with AggroLink 8 software,
Chrono-Log Corporation, Havertown, PA, USA). Platelet
rich plasma (PRP) and platelet poor plasma were obtained
by differential centrifugation of citrate blood as previously
described [2, 17]. Platelet aggregation in PRP was induced
with ADP at 5, 10 and 20 lM, with thrombin receptor
activating peptide (TRAP) at 15 and 25 lM, and arachi-
donic acid (AA) 1 mM.
Thrombelastography (TEG)
TEG was performed using citrate plasma samples
obtained prior to percutaneous coronary intervention
(PCI) according to the manufacturer’s instructions (TEG
5000 Thrombelastograph Hemostasis Analyzer System,
Haemonetics, MA, USA). Citrate plasma was mixed with
kaolin, inverted five times, and then loaded in a hepa-
rinase coated cup containing 20 ll of CaCl2. TEG was
stopped after maximal fibrin clot strength was recorded.
Time to fibrin formation (R), clot formation time (K),
angle (a), and maximal clot strength [G (dyn/cm2)] was
recorded.
Genotyping
Genomic DNA was extracted from whole-blood with the use
of Qiagen’s QIAamp DNA Blood Midi Kit (Germantown,
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MD, USA). Factor XIII Val34Leu (rs5985) SNP was ana-
lyzed using Bio-Rad Laboratories real-time PCR system.
Sequence specific primers were used to amplify the alleles of
interest, along with two allele-specific TaqMan probes,
purchased by Applied Biosystems, (Foster City, CA, USA).
Allelic discrimination was used to determine individual
genotypes (Optical system 3.1 software, Bio-Rad Labora-
tories, CA, USA).
ELISA
Citrated plasma was analyzed by ELISA assay according to
manufacturer’s instructions after appropriate dilutions for
fibrinogen (Alpco Diagnostics, USA) and FXIIIa concen-
trations (Abnova, USA).
Clinical endpoints
MI was defined according to the universal definition for
MI, as a rise of biomarkers of myocardial injury elevated
above the 99th percentile of the upper reference limit
(URL) in subjects presenting with symptoms of ischemia
[18]. PCI related MI was defined as a rise of creatinine
kinase MB fraction above 3 9 99th percentile of URL
when associated with prolonged symptoms suggestive of
myocardial ischemia, new ischemic ECG changes, angio-
graphically documented coronary occlusion, or imaging
evidence of loss of viable myocardium. Stent thrombosis
was defined as probable or definite according to Academic
Research Consortium criteria [1]. Bleeding was defined as
moderate or severe bleeding according to GUSTO criteria
[19]. Electronic medical records were examined for the
occurrence of clinical events as defined.
Statistics
SPSS statistics software package (Version 21, IBM, USA)
was used for analysis. Continuous variables are expressed
as mean ± SD. Categorical data are presented as percent
frequency and groups were compared using the Chi square
test. Student’s t test was used to compare normally dis-
tributed continuous data between two groups and for
genotype group comparisons one-way analysis of variance
was used.
Kaplan–Meier survival analysis was performed for
combined cardiovascular (CV) death/MI and MI alone,
according to Val34Leu genotypes with log-rank method.
Outcomes were censored at time of last clinical follow up.
Cox regression analysis was performed with adjustment for
age, gender, race, diabetes mellitus, PCI, MI, coronary
artery bypass grafting (CABG), hyperlipidemia, peripheral
vascular disease (PVD), smoking, body mass index (BMI),
and clopidogrel pretreatment in a forward stepwise model
to calculate hazard ratios associated with Val34Leu geno-
types and clinical outcomes (Table 3.)
Results
Baseline characteristics of the study subjects are described
according to FXIII Val34Leu polymorphisms in (Table 1). A
total of 211 patients were enrolled. The patients mean age
was 57.3 ± 10 years. The majority was male, white and
obese (Table 1), although a significant proportion of women
and African Americans were also enrolled. Among 211
patients in this study, 114 (54 %) were carriers of the Val/Val
genotype, 86 (40.8 %) were heterozygous allele carriers
(Val/Leu) and 11(5.2 %) were homozygous Leu/Leu geno-
type carriers. Genotype frequency distribution was consis-
tent with Hardy–Weinberg equilibrium (p = 0.31). The
majority of patients had undergone coronary stenting
(82 %), while the remainder was treated with dual anti-
platelet therapy after an acute coronary syndrome (18 %).
Overall clinical variables were well balanced among
genotype groups with no significant differences in clinical
variables. Importantly, major established CV risk factors
such as diabetes mellitus (DM), and smoking were not
significantly different among groups.
Platelet aggregation induced by ADP demonstrated wide
inter-individual variability during therapy with clopidogrel,
as previously documented [2, 3]. Among the three geno-
types, there was no significant difference in ADP induced
on treatment platelet aggregation during clopidogrel ther-
apy before and after adjustment for DM, obesity, smoking
and proton pump inhibitor therapy (Table 2). Similarly,
PAR-1 mediated aggregation stimulated by thrombin
receptor agonist peptide (TRAP) was not significantly
different among Val34Leu genotypes (Table 2). With the
exception of two individuals of Val34Val wild type, all
subjects were found to be aspirin responders as defined by
maximal platelet aggregation (MPA) \20 % by AA.
The three genotype groups did not differ significantly in
TEG-R, TEG-G, and TEG-a measurements (Fig. 1). How-
ever, TEG-K (clot formation time) significantly decreased
with increasing number of 34Leu alleles and a statistically
significant difference between the wild type (Val/Val) and
the homozygous genotype (Leu/Leu) could be detected
(1.68 ± 1.1 vs. 1.27 ± 0.3 min, p = 0.011; mean differ-
ence 0.41 (95 % CI 0.1–0.71) (Fig. 1). TEG-G was not sig-
nificantly different between homozygous carriers of the
34Leu allele and wild type individuals (3,263 ± 996 vs.
2,893 ± 1,088 dynes/cm2, p = 0.29) (Fig. 1). Fibrinogen
concentration (7.4 ± 4 vs. 9.2 ± 6 mg/ml; p = 0.13) and
FXIIIa levels (22.2 ± 9 vs. 24.1 ± 11 ng/ml; p = 0.5) were
not significantly different between carriers of Val34Leu and
wild type subjects.
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The mean duration of follow up was 3.0 ± 1.9 years.
Kaplan–Meier survival curves for MI and combined CV
death and MI endpoints are shown according to Val34Leu
genotypes (Fig. 2). Event free survival was highest in
individuals of 34Val wild type, with incrementally higher
event rates in heterozygous and homozygous carriers of the
34Leu variant. Cox regression analysis was performed after
adjustment for clinical variables and demographics (sup-
plemental online material). Clinical events are listed
according to genotypes (Table 3). Homozygous 34Leu was
Table 1 Demographics and clinical variables of subjects included in the study according to Val34Leu genotype
Clinical variables Total Val/Val Val/Leu Leu/Leu p value
Number of patients 211 (100 %) 114 (54 %) 86 (40.8 %) 11 (5.2 %)
Age (mean ± SD) (years) 57.3 ± 10 57 ± 9.7 58.4 ± 10 52 ± 10.7 0.13
Gender (%)
Male 121 (57 %) 63 (55 %) 50 (56 %) 8 (73 %) 0.53
Female 90 (43 %) 51 (45 %) 36 (44 %) 3 (27 %)
Race (%)
White 151 (72 %) 77 (68 %) 67 (78 %) 7 (64 %) 0.7
Black 56 (27 %) 34 (30 %) 18 (21 %) 4 (36 %)
Others 4 (2 %) 3 (3 %) 1 (1 %) 0 (0 %)
Smoking (%)
Non-smoker 115 (55 %) 61 (54 %) 51 (59 %) 3 (27 %) 0.13
Current smoker 96 (45 %) 53 (46 %) 35 (41 %) 8 (73 %)
Weight (kg) 95.2 ± 25 91.8 ± 21 98.1 ± 25 112.3 ± 47 0.16
Height (cm) 170.4 ± 11 169.3 ± 9 171.5 ± 10 173.9 ± 14 0.45
BMI (kg/m2) 32.8 ± 9 32.3 ± 6.7 32.9 ± 7.3 36.8 ± 7.5 0.3
Previous myocardial infarction (%) 143 (68 %) 82 (72 %) 54 (63 %) 7 (64 %) 0.3
Previous CABG (%) 46 (22 %) 24 (21 %) 22 (26 %) 0 (0 %) 0.15
Coronary stent placement (%) 167 (82 %) 94 (82 %) 70 (81 %) 9 (81 %) 0.98
Left ventricular ejection fraction (EF) (%) 49.7 ± 17 48.2 ± 20 51.7 ± 15 47.5 ± 15 0.59
DM (%) 91 (43 %) 49 (43 %) 39 (45 %) 3 (27 %) 0.52
Hypertension (%) 196 (93 %) 104 (91 %) 81 (94 %) 11 (100 %) 0.46
Hyperlipidemia (%) 186 (94 %) 108 (95 %) 79 (92 %) 11 (100 %) 0.48
PVD (%) 29 (14 %) 19 (17 %) 10 (12 %) 0 (0 %) 0.24
ACE-I/ARB (%) 165 (78 %) 90 (79 %) 65 (76 %) 10 (91 %) 0.23
Betablocker (%) 196 (93 %) 106 (93 %) 80 (93 %) 10 (91 %) 0.69
Calcium channel blocker (%) 50 (24 %) 30 (26 %) 18 (21 %) 2 (18 %) 0.61
Proton pump inhibitor (%) 66 (31 %) 34 (30 %) 28 (33 %) 4 (36 %) 0.86
Statin (%) 176 (83 %) 98 (86 %) 70 (81 %) 8 (73 %) 0.36
Clopidogrel loading dose (%) 94 (50 %) 56 (49 %) 45 (52 %) 4 (36 %) 0.6
ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker. Values represent mean ± SD
Table 2 MPA induced by ADP and TRAP measured by LTA according to Val34Leu genotypes
MPA ADP
5 lM (%)
MPA ADP
10 lM (%)
MPA ADP
20 lM (%)
MPA TRAP
15 lM (%)
MPA TRAP
25 lM (%)
Val/Val (n = 114) 33 ± 15 41.6 ± 16 47 ± 16 77.4 ± 9 79.3 ± 10
Val/Leu (n = 86) 32.3 ± 16 39.2 ± 18 45.1 ± 18 75.6 ± 12 79.2 ± 11
Leu/Leu (n = 11) 34.2 ± 12 37.4 ± 15 49.1 ± 11 78 ± 5 81 ± 4
p value 0.9 0.53 0.63 0.67 0.81
p value for linear regression analysis after multivariate adjustment for DM, smoking, proton pump inhibitor use, and weight
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associated with the highest hazard ratio (HR) for recurrent
MI (HR = 6.7; 95 % CI 2.1–21; p = 0.001) as compared
to wild type individuals, with a relatively smaller risk in all
carriers of the 34Leu allele (HR = 2.8; 95 % CI 1.2–6.8;
p = 0.02) (Table 3). Twelve patients (5.7 %) died during
follow-up, with half of deaths due to non-CV causes.
Deaths due to CV causes were evenly distributed and the
risk of all cause death was not significantly different across
Fig. 1 Thrombelastography measurements grouped according to Val34Leu genotypes. a TEG-K: fibrin clot formation time. b TEG-angle.
c TEG-G: maximal fibrin clot strength. d TEG-R: time to clot formation
Fig. 2 Kaplan-Meier event free survival curves for cardiovascular death or myocardial infarction (a) and myocardial infarction alone (b),
grouped according to Val34Leu genotypes
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genotypes (Table 3). Homozygous 34Leu was associated
with a HR of 6.2 (95 % CI 2.1–18; p = 0.001) for recur-
rent MI or death as compared to wild type individuals,
whereas for all carriers of the 34Leu allele the HR was 2.9
(95 % CI 1.3–6.1; p = 0.006) (Table 3). Stent thrombosis
and bleeding events were not significantly different among
genotypes (Table 3). The primary combined endpoint of
CV death and MI occurred less frequently in patients who
had been treated with PCI as compared to medical treat-
ment after ACS (HR = 0.5, 95 % CI 0.2–1.2; p = 0.1).
Discussion
In regard to the association of Val34Leu polymorphism with
coronary artery disease, there have been conflicting reports,
and the results of our study are in contrast to the conclusions
of some previous studies. In essence, some case–control
studies examining the prevalence of 34Leu allele in survi-
vors of acute MI found a reduced number of patients with
34Leu alleles as compared with matched healthy controls
[14, 20–24]. Although more recent reports demonstrated
neutral results in larger patient series, 34Leu allele has been
suggested to be protective for the development of coronary
artery disease and early MI. In contrast, carriers of 34Leu
have been shown to exhibit resistance to fibrinolysis
administered during ST elevation MI with reduced lytic
success, worse reperfusion, and worse clinical outcome [25,
26]. Since many of the case–control studies that examined
the prevalence of Val34Leu allele recruited MI survivors
during the thrombolytic era prior to widespread adoption of
primary PCI in acute MI, it is possible that the protective
effect of 34Leu allele may at least in part be due to survival
bias [23]. In addition, despite the confirmation of a modest
protective effect of 34Leu on incidence of MI in a meta-
analysis, publication bias could not be excluded by the
authors of the meta-analysis [23]. Sylvain et al. [14] pro-
spectively followed 228 young survivors of acute MI and
could not demonstrate a significant difference in survival
between carriers of Val34Leu variant and wild type indi-
viduals using a dominant model of inheritance. Event rates
were relatively low despite long term follow-up, with a non-
significant trend towards increased risk in carriers of 34Leu
allele as compared to wild type subjects (HR 1.09; 95 % CI
0.46–2.6; p = 0.85) [14].
While questions remain regarding contributions of hae-
mostatic genes to the de-novo incidence of MI in case–
control studies, the implantation of coronary stents in coro-
nary arteries changes the risk equation in regards to the rel-
ative importance of small differences in prothrombotic
phenotype. This is evidenced by the example of increased
protection derived from P2Y12 inhibition by clopidogrel in
subjects treated with coronary stenting as compared toT
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patients treated medically after an acute coronary syndrome
[27, 28]. In theory, a similar analogy could explain differ-
ences of gene-risk association observed with Val34Leu in
patients with coronary artery disease treated medically as
compared to PCI.
Overall, the findings of our study suggest a dose depen-
dent effect of 34Leu allele on ischemic risk in subjects with
coronary artery disease with highest risk observed in
homozygous carriers of the allele. Therefore, a dose geno-
type model appears preferable over a dominant model in
examining thrombotic risk after coronary stenting in future
studies. Ischemic events included a significant number of late
and very late stent thrombosis as well as spontaneous MIs.
Since FXIII has been implicated in platelet adhesion to
fibrin polymer, we intended to examine the association of
Val34Leu with clopidogrel platelet inhibition, a potential
confounder of ischemic risk after coronary stenting.
Importantly, we could not find an association of Val34Leu
with ADP induced platelet reactivity, a measure consis-
tently associated with higher rates of stent thrombosis after
coronary stenting. Limitations of our study include the
relatively small number of subjects homozygous for the
minor allele variant, and possible unidentified confounding
factors in carriers of 34Leu variants.
In conclusion, among patients with coronary artery
disease treated with dual antiplatelet therapy, carriers of
Val34Leu variant demonstrate increased risk of recurrent
MI and the combined endpoint of CV death and MI as
compared to patients of wild type. Homozygous individu-
als for 34Leu exhibit faster rate of fibrin clot formation
measured by TEG and increased risk for MI and the
combined endpoint of CV death and MI as compared to
heterozygous subjects or subjects of wild type. Further
validation in large prospective studies examining ischemic
events rates after coronary stenting is warranted.
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